United States · Research
Research
Elicio Therapeutics is a clinical-stage biotechnology company based in Boston, Massachusetts. Founded in 2011, the company specializes in developing lymph node-targeted immunotherapies aimed at treating aggressive cancers. Elicio focuses on harnessing the natural power of lymph nodes to enhance immune responses against tumors, with the goal of improving patient outcomes. The company utilizes its proprietary Amphiphile (AMP) platform to create immunotherapies that directly target lymph nodes, promoting the activation and proliferation of cancer-fighting T cells. Elicio's product pipeline includes ELI-002, a peptide vaccine in Phase II trials for pancreatic ductal adenocarcinoma, as well as ELI-007 and ELI-008, which target specific gene mutations in solid tumors. Elicio is committed to advancing therapies through clinical trials, emphasizing precision delivery and sustained immune activation.
2011
Founded
Research
Industry
United States
Location
1,242,500
Ranking
32 employees
Size
Get full access to view complete information
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
